|875 Third Avenue , New York, NY 10022|
|Fund Manager||Team Managed|
The fund seeks to maximize total return consistent with preservation of capital and prudent investment management, by investing for both current income and capital appreciation. Under normal circumstances, the fund invests at least 80% of net assets, plus the amount of any borrowings for investment purposes, in bonds of any maturity. The fund invests mainly in investment grade US dollar denominated fixed income securities,including corporate bonds, US government and agency bonds and mortgage- and asset-backed securities. The fund may invest up to 35%of total assets in non-investment grade securities (high yield and junk bonds), including securities in default. Compared to investment grade securities, non-investment grade securities generally pay higher yields but have higher volatility and higher risk of default on payments. The fund may also invest in cash or money market instruments to maintain liquidity.
|Asset Type||% Of Allocation|
|Total Net Assets||7.79 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$500|
|Timeframe||Average Annual Current Performance Monthly As Of 08/31/2021||Average Annual Current Performance Quarterly As Of 05/31/2021||Avg Annual Current Performance Monthly As Of 08/31/2021||Avg Annual Current Performance Quarterly As Of 05/31/2021|
|Life Of Fund||
Join the Action Alerts PLUS Community today!
Micron topped analysts' fourth quarter expectations but provided tepid outlook for the first quarter.
Wolfe Research upgraded Chewy to outperform, saying a drop in net new customer additions should reverse in fiscal 2022.
Ahead of third-quarter earnings season, James 'Rev Shark' Deporre has some thoughts on what investors should be thinking about.
Gogo, Huntsman, Thor Industries, United Natural Foods and Sonoma Pharmaceuticals are five top stock gainers for Tuesday.
Stocks end sharply lower Tuesday as Wall Street contends with rolling blackouts in China, record high energy prices in Europe and gas line-ups in Britain.
Aurora Cannabis had a tough quarter, but Cowen analysts still expect strong growth margins in 2022.